DK2487166T3 - Modulators of the pharmacokinetic properties of therapeutics - Google Patents

Modulators of the pharmacokinetic properties of therapeutics Download PDF

Info

Publication number
DK2487166T3
DK2487166T3 DK12167596.1T DK12167596T DK2487166T3 DK 2487166 T3 DK2487166 T3 DK 2487166T3 DK 12167596 T DK12167596 T DK 12167596T DK 2487166 T3 DK2487166 T3 DK 2487166T3
Authority
DK
Denmark
Prior art keywords
compound
mmol
mixture
tenofovir disoproxil
alkyl
Prior art date
Application number
DK12167596.1T
Other languages
Danish (da)
English (en)
Inventor
Manoj C Desai
Allen Y Hong
Hon C Hui
Hongtao Liu
Radall W Vivian
Lianhong Xu
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39522375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2487166(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DK2487166T3 publication Critical patent/DK2487166T3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK12167596.1T 2007-02-23 2008-02-22 Modulators of the pharmacokinetic properties of therapeutics DK2487166T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90322807P 2007-02-23 2007-02-23
US95871607P 2007-07-06 2007-07-06
EP08743531.9A EP2118082B1 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics

Publications (1)

Publication Number Publication Date
DK2487166T3 true DK2487166T3 (en) 2017-02-20

Family

ID=39522375

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12167596.1T DK2487166T3 (en) 2007-02-23 2008-02-22 Modulators of the pharmacokinetic properties of therapeutics
DK16180589.0T DK3150586T3 (da) 2007-02-23 2008-02-22 Modulatorer af farmakokinetiske egenskaber af terapeutika

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16180589.0T DK3150586T3 (da) 2007-02-23 2008-02-22 Modulatorer af farmakokinetiske egenskaber af terapeutika

Country Status (32)

Country Link
US (7) US8148374B2 (enExample)
EP (5) EP4403221A3 (enExample)
JP (9) JP4881446B2 (enExample)
KR (2) KR101577698B1 (enExample)
CN (2) CN101679325B (enExample)
AP (2) AP3915A (enExample)
AR (1) AR065439A1 (enExample)
AU (1) AU2008218186C1 (enExample)
BR (1) BRPI0807581A2 (enExample)
CA (1) CA2678907C (enExample)
CY (9) CY1118292T1 (enExample)
DK (2) DK2487166T3 (enExample)
EA (1) EA019893B1 (enExample)
ES (6) ES2603645T3 (enExample)
FI (1) FI2487161T4 (enExample)
FR (4) FR17C1002I2 (enExample)
HR (5) HRP20161476T4 (enExample)
HU (6) HUE029866T2 (enExample)
IL (1) IL200550A0 (enExample)
LT (9) LT2487162T (enExample)
LU (1) LUC00156I2 (enExample)
MX (1) MX2009008935A (enExample)
NL (1) NL301045I2 (enExample)
NO (4) NO2017003I1 (enExample)
NZ (1) NZ579802A (enExample)
PL (3) PL3150586T3 (enExample)
PT (6) PT2487161T (enExample)
SG (2) SG183059A1 (enExample)
SI (1) SI3150586T1 (enExample)
TW (1) TWI533868B (enExample)
WO (1) WO2008103949A1 (enExample)
ZA (1) ZA200905882B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
TR201906416T4 (tr) * 2004-07-27 2019-05-21 Gilead Sciences Inc Hiv inhibitörü bileşiklerin fosfonat analogları.
US8067449B2 (en) 2006-07-07 2011-11-29 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
EP2465856A3 (en) * 2006-08-31 2012-12-12 Abbott Laboratories Cytochrome P450 oxidase inhibitors and uses thereof
ES2603645T3 (es) 2007-02-23 2017-02-28 Gilead Sciences, Inc. Moduladores de las propiedades farmacocinéticas de agentes terapéuticos
UA101312C2 (ru) 2007-02-23 2013-03-25 Гіліад Сайєнсіз, Інк. Модуляторы фармакокинетических свойств терапевтических препаратов
JP2011503231A (ja) * 2007-11-20 2011-01-27 コンサート ファーマシューティカルズ インコーポレイテッド Ｈｃｖ感染処置のためのペプチド
WO2009088719A1 (en) * 2008-01-04 2009-07-16 Gilead Sciences, Inc. Inhibitors of cytochrome p450
KR101784647B1 (ko) 2008-05-02 2017-10-11 길리애드 사이언시즈, 인코포레이티드 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도
BRPI0915878A2 (pt) * 2008-07-08 2015-11-03 Gilead Sciences Inc sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
EA026557B1 (ru) 2008-12-09 2017-04-28 Джилид Сайэнс, Инк. Промежуточные соединения для получения модуляторов толл-подобных рецепторов
DK2393485T3 (en) * 2009-02-06 2015-10-26 Gilead Sciences Inc Bilayer COVERING ELVITEGRAVIR, COBICISTAT, emtricitabine and tenofovir
AU2015200637C1 (en) * 2009-02-06 2017-08-03 Gilead Sciences, Inc. Tablets for combination therapy
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
WO2010151672A2 (en) * 2009-06-26 2010-12-29 Georgetown University Amino acid derived ureas
SI2932970T1 (en) 2010-01-27 2018-07-31 Viiv Healthcare Company Antiviral therapy
WO2012045007A1 (en) 2010-10-01 2012-04-05 Gilead Sciences, Inc. Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester
JP2014500261A (ja) * 2010-11-19 2014-01-09 ギリアード サイエンシーズ， インコーポレイテッド リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物
WO2012088178A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
US8987313B2 (en) 2010-12-21 2015-03-24 Gilead Sciences, Inc. Inhibitors of cytochrome P450
US20130280212A1 (en) * 2010-12-21 2013-10-24 Gilead Sciences, Inc Inhibitors of cytochrome p450
EP2472320A2 (en) 2010-12-30 2012-07-04 Rohm and Haas Electronic Materials LLC Compositions comprising base-reactive component and processes for photolithography
CA2836768A1 (en) * 2011-05-02 2012-11-08 Gilead Sciences, Inc. Amorphous solid salts
HUE035241T2 (en) 2011-07-07 2018-05-02 Janssen Sciences Ireland Uc Darunavir combination formulations
AU2012296622C1 (en) 2011-08-16 2017-02-16 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
MX2014009344A (es) 2012-02-03 2015-05-11 Gilead Sciences Inc Metodos e intermediarios para preparar agentes farmaceuticos.
AU2012327170A1 (en) * 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
NZ629896A (en) * 2012-02-03 2016-03-31 Gilead Sciences Inc Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
CN103694196A (zh) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
WO2014057498A2 (en) 2012-10-08 2014-04-17 Mylan Laboratories Ltd. Process for the preparation of cobicistat intermediates
CA2885763C (en) * 2012-10-23 2021-04-06 Cipla Limited Pharmaceutical antiretroviral composition
BR112015014714B1 (pt) 2012-12-21 2018-12-26 Gilead Sciences, Inc. compostos carbamoilpiridona policíclicos, composição farmacêutica que os compreende e seu uso farmacêutico
WO2014105777A1 (en) 2012-12-26 2014-07-03 Assia Chemical Industries Ltd. Cobicostat dichlohydrate salt
AU2014286993B2 (en) 2013-07-12 2018-10-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections
NO2865735T3 (enExample) 2013-07-12 2018-07-21
WO2015054133A1 (en) 2013-10-07 2015-04-16 Bristol-Myers Squibb Company Hiv treatment formulation of atazanavir and cobicistat
ES2689654T3 (es) 2013-12-03 2018-11-15 Mylan Laboratories Ltd. Preparación de productos intermedios de cobicistat
WO2015145324A1 (en) 2014-03-25 2015-10-01 Mylan Laboratories Ltd Process for the preparation of cobicistat
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (enExample) 2014-06-20 2018-06-23
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
UA120856C2 (uk) * 2014-07-17 2020-02-25 Кхді Фаундейшн, Інк. Способи та композиції для лікування розладів, пов'язаних з віл
PT3194401T (pt) 2014-09-16 2020-12-23 Gilead Sciences Inc Formas sólidas de modulador de recetor tipo toll
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
TR201905009T4 (tr) 2015-04-02 2019-05-21 Gilead Sciences Inc Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
CN105198829B (zh) * 2015-08-15 2017-10-31 浙江永宁药业股份有限公司 一种可比司他中间体的制备方法及其中间体和用途
CN107513046B (zh) * 2016-06-15 2019-12-13 江苏欧信制药有限公司 一种可比司他的合成方法
WO2018026835A1 (en) * 2016-08-04 2018-02-08 Gilead Sciences, Inc. Cobicistat for use in cancer treatments
US20190175511A1 (en) 2016-08-08 2019-06-13 Hetero Labs Limited A Multi-Class Anti-Retroviral Composition
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
KR101908853B1 (ko) * 2017-05-17 2018-10-16 경북대학교 산학협력단 아세틸시코닌을 유효성분으로 함유하는 시토크롬 p450 동효소 억제용 조성물
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
BR122022008466B1 (pt) 2017-12-07 2023-12-05 Emory University Uso de um composto
CN109912530A (zh) * 2017-12-13 2019-06-21 上海奥博生物医药技术有限公司 一种可比司他原料杂质的制备方法
JP7232845B2 (ja) * 2018-01-30 2023-03-03 パンベラ セラピューティクス インコーポレイテッド （６ｓ、１５ｓ）－３，８，１３，１８－テトラアザイコサン－６，１５－ジオールの製造方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US199851A (en) * 1878-01-29 Improvement in circular saws
US115665A (en) * 1871-06-06 Improvement in folding-steps for carriages
US181902A (en) * 1876-09-05 Improvement in bell toys
US143314A (en) * 1873-09-30 Improvement in condenser-tube fastenings
US108617A (en) * 1870-10-25 Improvement in ore-pulverizers
US191319A (en) * 1877-05-29 Improvement in stoves
US77295A (en) * 1868-04-28 theqdoee krausch
US127689A (en) * 1872-06-11 Improvement in differential pulley-blocks
US99902A (en) * 1870-02-15 1870-02-15 Improvement in adjustable dials for travelers watches
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US3882114A (en) 1967-10-26 1975-05-06 Oreal N-(morpholinomethyl carbamyl) cysteamine and glycine
GB1241024A (en) 1968-10-29 1971-07-28 Boehringer Sohn Ingelheim Pharmaceutical tablet base and a process for its manufacture
CA926708A (en) 1970-06-15 1973-05-22 Oushima Yoshitaka Process for producing spherical pellets
GB1339764A (en) 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
CH586568A5 (enExample) 1972-04-10 1977-04-15 Hoffmann La Roche
US3957774A (en) 1972-04-17 1976-05-18 L'oreal N-morpholinomethyl-n-'-substituted ethyl and propylureas
DE2845326C2 (de) 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
HU186777B (en) 1981-07-09 1985-09-30 Magyar Tudomanyos Akademia Process for producing complex-forming agents of crown-ether base and ionoselective membranelektrodes containing them
US4603143A (en) 1983-05-02 1986-07-29 Basf Corporation Free-flowing, high density, fat soluble vitamin powders with improved stability
GB8413191D0 (en) 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
FR2631620B1 (fr) 1988-05-19 1990-07-27 Rhone Poulenc Chimie Nouvelle silice precipitee absorbante et composition a base de cette s ilice
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5362912A (en) * 1989-05-23 1994-11-08 Abbott Laboratories Process for the preparation of a substituted diaminodiol
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
EP0428849A3 (en) 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
IE20010533A1 (en) 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
JPH06127981A (ja) 1992-03-03 1994-05-10 Fuainiteii Kk 複合複層ガラス及びそれを使用した窓
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ES2174992T3 (es) 1992-12-29 2002-11-16 Abbott Lab Productos intermediarios para la obtencion de compuestos inhibidores de proteasas retrovirales.
WO1995005808A1 (en) 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5763464A (en) 1995-11-22 1998-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same
JP4064476B2 (ja) 1996-03-29 2008-03-19 エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド 二酸化珪素を有する球状凝集した澱粉
US6348216B1 (en) 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
US6361794B1 (en) 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JP4494539B2 (ja) 1997-02-28 2010-06-30 ディーエスエム アイピー アセッツ ビー．ブイ． 流動自由な乾燥粒子
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
FR2767071B1 (fr) 1997-08-06 1999-09-10 Rhodia Chimie Sa Composition comprenant un liquide absorbe sur un support a base de silice precipitee
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
FR2773994B1 (fr) 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
JP4027535B2 (ja) 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有した粉末
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
HU229501B1 (hu) 1999-06-04 2014-01-28 Abbvie Inc HIV proteáz gátló vegyületet tartalmazó gyógyszerkészítmények
OA12053A (en) 1999-10-06 2006-05-02 Tibotec Pharm Ltd HexahydrofuroÄ2,3-bÜfuran-3-yl-N-ä3-Ä(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)aminoÜ-1-benzyl-2-hydroxypropylücarbamate as retroviral protease inhibitor.
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US6448245B1 (en) 2000-05-04 2002-09-10 The United States Of America As Represented By The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
US20030035834A1 (en) 2000-05-26 2003-02-20 Pawan Seth Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
KR20030040389A (ko) 2000-09-19 2003-05-22 다이이찌 세이야꾸 가부시기가이샤 의약 조성물
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6524615B2 (en) 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
DE10112651A1 (de) 2001-03-16 2002-09-19 Degussa Inhomogene Kieselsäuren als Trägermaterial
AP2003002900A0 (en) 2001-05-01 2003-12-31 Pfizer Prod Inc Method for manufacturing a low dose pharmaceutical composition
DE10126163A1 (de) 2001-05-30 2002-12-05 Degussa Pharmazeutische Zubereitungen
RU2330642C2 (ru) 2001-07-06 2008-08-10 Лайфсайкл Фарма А/С Регулируемая агломерация
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US7815936B2 (en) 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
WO2003047551A1 (en) 2001-11-29 2003-06-12 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US7285566B2 (en) * 2002-01-07 2007-10-23 Erickson John W Resistance-repellent retroviral protease inhibitors
CA2472372C (en) * 2002-01-17 2010-08-17 Melissa Egbertson Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
US6926906B2 (en) 2002-02-20 2005-08-09 M./S. Strides, Inc. Orally administrable pharmaceutical formulation
US6726448B2 (en) 2002-05-15 2004-04-27 General Electric Company Ceramic turbine shroud
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
DE10250711A1 (de) 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
EP3406596A1 (en) * 2002-11-20 2018-11-28 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
US7189416B2 (en) 2002-11-23 2007-03-13 Glykon Technologies Group, Llc Method for stable and controlled delivery of (-)-hydroxycitric acid
JP2004184681A (ja) 2002-12-03 2004-07-02 Konica Minolta Holdings Inc 熱現像感光材料
KR20090053867A (ko) 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
CA2516448A1 (en) 2003-02-19 2004-09-02 H. Lundbeck A/S Method for preparation of an agglomerate using melt agglomeration
FR2851918B1 (fr) 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
JP4018664B2 (ja) 2003-04-30 2007-12-05 第一三共株式会社 安定化固形製剤
DE10337198A1 (de) 2003-08-13 2005-03-17 Degussa Ag Träger auf Basis von Granulaten, die aus pyrogen hergestelltem Siliciumdioxiden hergestellt sind
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2005075826A (ja) 2003-08-29 2005-03-24 Boehringer Ingelheim Internatl Gmbh 多孔質シリカ担体を含有する徐放性製剤
JP2005091988A (ja) 2003-09-19 2005-04-07 Konica Minolta Medical & Graphic Inc 熱現像感光材料及び画像形成方法
WO2005032525A1 (en) 2003-10-03 2005-04-14 Lifecycle Pharma A/S A method for preparing modified release pharmaceutical compositions
US20050096390A1 (en) 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
US20050095287A1 (en) 2003-10-29 2005-05-05 Matharu Amol S. Fosinopril composition
US7834043B2 (en) 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
US20070298108A1 (en) 2004-03-01 2007-12-27 Peter Svete Pharmaceutical Formulation
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050238675A1 (en) 2004-04-26 2005-10-27 Wenjie Li Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US8633219B2 (en) 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
JP2006003701A (ja) 2004-06-18 2006-01-05 Konica Minolta Medical & Graphic Inc 熱現像感光材料および画像形成方法
WO2006000229A2 (en) 2004-06-28 2006-01-05 Lifecycle Pharma A/S Porous tablets as carriers for liquid formulations
MXPA06015108A (es) 2004-07-06 2007-03-26 Abbott Lab Profarmacos inhibidores de la proteasa del virus de la inmunodeficiencia humana.
AR045841A1 (es) 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
EP2266579A1 (en) 2004-10-19 2010-12-29 Achillion Pharmaceuticals, Inc. Pharmaceutical composition comprising elvucitavine
US7786153B2 (en) 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US20070014854A1 (en) 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
US8048449B2 (en) 2005-12-27 2011-11-01 Jubilant Organosys Ltd. Mouth dissolving pharmaceutical composition and process for preparing the same
US20090233964A1 (en) 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EA018544B1 (ru) 2005-12-30 2013-08-30 Джилид Сайэнс, Инк. Способ лечения ретровирусной инфекции
EA018606B1 (ru) 2006-01-05 2013-09-30 Велоксис Фармасьютикалз А/С Распадающиеся загружаемые таблетки
US20100285157A1 (en) 2006-02-20 2010-11-11 Asahi Breweries, Ltd Granules, tablets and method of producing the same
EP1998759A2 (en) 2006-03-23 2008-12-10 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
US8067449B2 (en) 2006-07-07 2011-11-29 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
WO2008017867A2 (en) 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition with at least one water insoluble polymer
EP2465856A3 (en) 2006-08-31 2012-12-12 Abbott Laboratories Cytochrome P450 oxidase inhibitors and uses thereof
US20090281132A1 (en) 2006-09-04 2009-11-12 Kiran Kumar Narsaiah Velaveni Pharmaceutical formulation for use in hiv therapy
US7749537B2 (en) 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
ES2603645T3 (es) 2007-02-23 2017-02-28 Gilead Sciences, Inc. Moduladores de las propiedades farmacocinéticas de agentes terapéuticos
AR067184A1 (es) 2007-06-29 2009-09-30 Gilead Sciences Inc Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
MX2009013829A (es) 2007-06-29 2010-03-10 Gilead Sciences Inc Composiciones terapeuticas y su uso.
ES2438275T3 (es) 2007-07-06 2014-01-16 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de agentes terapéuticos
DK2416157T3 (da) 2007-12-27 2014-08-18 Baxter Int Fremgangsmåde og sammensætninger til specifik påvisning af fysiologisk acceptable polymermolekyler
KR101784647B1 (ko) * 2008-05-02 2017-10-11 길리애드 사이언시즈, 인코포레이티드 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도
DK2393485T3 (en) * 2009-02-06 2015-10-26 Gilead Sciences Inc Bilayer COVERING ELVITEGRAVIR, COBICISTAT, emtricitabine and tenofovir
EP2238979A1 (en) 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
NZ629896A (en) 2012-02-03 2016-03-31 Gilead Sciences Inc Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections

Also Published As

Publication number Publication date
CY2017001PI2 (el) 2017-09-13
ES2603617T3 (es) 2017-02-28
HRP20200349T1 (hr) 2020-06-12
AU2008218186B2 (en) 2014-01-23
FR17C1000I2 (fr) 2019-03-22
HRP20161476T1 (hr) 2016-12-16
CY2017001PI1 (el) 2017-09-13
JP2019059790A (ja) 2019-04-18
JP2015078241A (ja) 2015-04-23
PT2487161T (pt) 2016-11-10
NO2017002I1 (no) 2017-01-12
CN101679325A (zh) 2010-03-24
FR17C1001I2 (fr) 2019-05-17
TWI533868B (zh) 2016-05-21
FR17C1000I1 (fr) 2017-03-17
JP6147282B2 (ja) 2017-06-14
JP6147388B2 (ja) 2017-06-14
CY1118232T1 (el) 2017-06-28
FR20C1021I1 (fr) 2020-07-31
ES2779826T3 (es) 2020-08-20
EA019893B1 (ru) 2014-07-30
CY2020011I1 (el) 2020-11-25
LTC2487163I2 (lt) 2022-06-27
SG10201705929QA (en) 2017-08-30
EP4403221A3 (en) 2024-10-09
NO2017002I2 (no) 2017-01-12
EP2118082B1 (en) 2014-10-01
CN103435570B (zh) 2015-06-10
ZA200905882B (en) 2018-12-19
TW200904419A (en) 2009-02-01
LUC00156I1 (enExample) 2020-06-02
LTC3150586I2 (lt) 2022-05-10
CY1122761T1 (el) 2020-11-25
CY2017002I2 (el) 2017-06-28
LTC2487162I2 (lt) 2022-06-27
NL301045I2 (nl) 2025-12-02
PL2487162T3 (pl) 2017-03-31
CN101679325B (zh) 2013-08-28
JP4881446B2 (ja) 2012-02-22
ES2602784T3 (es) 2017-02-22
NO2020011I1 (no) 2020-06-05
AU2008218186C1 (en) 2014-07-17
US20100189687A1 (en) 2010-07-29
LT2487161T (lt) 2016-11-10
PT2487162T (pt) 2016-11-23
LTPA2020508I1 (lt) 2020-06-25
EP3150586B1 (en) 2020-01-08
PT3150586T (pt) 2020-03-31
HUS2000013I1 (hu) 2020-06-29
CY2017003I1 (el) 2017-06-28
LUC00156I2 (enExample) 2021-02-17
PT2487166T (pt) 2016-10-17
HRP20161428T1 (hr) 2016-12-16
HRP20161502T1 (hr) 2016-12-16
KR20150056665A (ko) 2015-05-26
HRP20161476T4 (hr) 2024-07-05
LTC2487166I2 (lt) 2021-10-11
CA2678907C (en) 2014-06-17
AP2986A (en) 2014-09-30
EP2487161B2 (en) 2024-06-05
FI2487161T4 (fi) 2024-06-06
EP2487161B1 (en) 2016-08-10
HK1137451A1 (en) 2010-07-30
AP3915A (en) 2016-11-29
LT2487162T (lt) 2016-11-10
EP4403221A2 (en) 2024-07-24
EP3689353A1 (en) 2020-08-05
LT2487166T (lt) 2016-11-10
CN103435570A (zh) 2013-12-11
EP3150586A1 (en) 2017-04-05
JP2014088441A (ja) 2014-05-15
JP2010519314A (ja) 2010-06-03
KR101664154B1 (ko) 2016-10-10
US20120237478A1 (en) 2012-09-20
AP2009004964A0 (en) 2009-10-31
SG183059A1 (en) 2012-08-30
PT2118082E (pt) 2014-12-12
KR101577698B1 (ko) 2015-12-15
AR065439A1 (es) 2009-06-10
JP5554300B2 (ja) 2014-07-23
HUS1600054I1 (hu) 2017-01-30
CY1118227T1 (el) 2017-06-28
US20160069915A1 (en) 2016-03-10
WO2008103949A1 (en) 2008-08-28
JP2011231132A (ja) 2011-11-17
FR17C1002I1 (fr) 2017-03-17
US8486942B2 (en) 2013-07-16
ES2601820T3 (es) 2017-02-16
NZ579802A (en) 2012-04-27
AU2008218186A1 (en) 2008-08-28
CY2017003I2 (el) 2017-06-28
US20170158647A1 (en) 2017-06-08
CY1118219T1 (el) 2017-06-28
ES2603645T3 (es) 2017-02-28
CY2020011I2 (el) 2020-11-25
BRPI0807581A2 (pt) 2014-07-01
NO2017001I1 (no) 2017-01-12
LTPA2016039I1 (lt) 2017-01-10
CY1118292T1 (el) 2017-06-28
EA200901155A1 (ru) 2010-02-26
KR20090122261A (ko) 2009-11-26
SI3150586T1 (sl) 2020-03-31
CY2017002I1 (el) 2017-06-28
ES2601820T5 (es) 2024-10-31
US8148374B2 (en) 2012-04-03
LT2487163T (lt) 2016-10-25
JP6192776B2 (ja) 2017-09-06
DK3150586T3 (da) 2020-02-17
JP2021001236A (ja) 2021-01-07
LT3150586T (lt) 2020-03-10
ES2525454T3 (es) 2014-12-23
JP2016172773A (ja) 2016-09-29
AP2013007042A0 (en) 2013-08-31
EP2118082A1 (en) 2009-11-18
LTPA2016038I1 (lt) 2017-01-10
US20140017199A1 (en) 2014-01-16
HUE029842T2 (en) 2017-04-28
IL200550A0 (en) 2010-05-17
PL3150586T3 (pl) 2020-06-01
EP2487161A1 (en) 2012-08-15
PL2487161T3 (pl) 2017-03-31
US20080207620A1 (en) 2008-08-28
HRP20161371T1 (hr) 2016-12-02
US9891239B2 (en) 2018-02-13
JP2017171695A (ja) 2017-09-28
LTPA2016040I1 (lt) 2017-01-10
HUE031707T2 (en) 2017-07-28
JP2016121193A (ja) 2016-07-07
HUE029866T2 (en) 2017-03-28
PT2487163T (pt) 2016-11-21
US20150139948A1 (en) 2015-05-21
HUE029843T2 (en) 2017-04-28
NO2017003I1 (no) 2017-01-12
FR17C1002I2 (fr) 2019-03-22
PL2487161T5 (pl) 2024-09-09
CA2678907A1 (en) 2008-08-28
FR17C1001I1 (fr) 2017-03-17
MX2009008935A (es) 2009-11-02

Similar Documents

Publication Publication Date Title
DK2487166T3 (en) Modulators of the pharmacokinetic properties of therapeutics
DK2049506T3 (en) MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
DK2487161T3 (en) Modulators of the pharmacokinetic properties of therapeutic agents
AU2015204378B2 (en) Modulators of pharmacokinetic properties of therapeutics
AU2015234299B2 (en) Modulators of pharmacokinetic properties of therapeutics
HK1235768B (en) Modulators of pharmacokinetic properties of therapeutics
HK1174904B (en) Modulators of pharmacokinetic properties of therapeutics
HK1174901B (en) Modulators of pharmacokinetic properties of therapeutics
HK1126485B (en) Modulators of pharmacokinetic properties of therapeutics
HK1174906B (en) Modulators of pharmacokinetic properties of therapeutics
HK1174900A (en) Modulators of pharmacokinetic properties of therapeutics
HK1174905B (en) Modulators of pharmacokinetic properties of therapeutics
HK1168593B (en) Modulators of pharmacokinetic properties of therapeutics
HK1232217B (en) Modulators of pharmacokinetic properties of therapeutics
HK1235768A1 (en) Modulators of pharmacokinetic properties of therapeutics
HK1235768A (en) Modulators of pharmacokinetic properties of therapeutics
HK40031994A (en) Modulators of pharmacokinetic properties of therapeutics
HK1168593A (en) Modulators of pharmacokinetic properties of therapeutics